What is VSBC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VSBC?

P/E (TTM) is n/a and 52-week range is $0.01 to $0.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VSBC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VSBC?

The company profile lists revenue (TTM) near $7M, net income (TTM) near $1M, EPS (TTM) near $-0.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vitaspring Biomedical Co. Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Riverside, California, US, 207M shares outstanding, ISIN US92851B1026 when available from company profile and filing metadata.

Vitaspring Biomedical Co. Ltd (VSBC) Stock Analysis & Quote

Vitaspring Biomedical Co. Ltd

$VSBC

Health Care · Biotechnology

Run Scenarios

$0.00

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

VitaSpring Biomedical Co. Ltd. engages in the research and development of stem cell applications in regenerative medicine and the establishment of advanced medical research centers and high standard cell production centers. The company is headquartered in Riverside, California and currently employs 0 full-time employees. The company went IPO on 2019-10-01. The firm invests in research and development of stem cell applications in regenerative medicine, establishes advanced medical research centers and cell production centers, and provides GTP standard stem cell preparations for the development of cellular drugs. The GTP Cell Center is the basis for its business, which is cross-domain in biotechnology medical treatment, medicine and medical materials, and focuses on the development of cell medical treatment. Its GTP standard stem cell production center is in Taipei, Taiwan for mass production of its mesenchymal stem cell (MSC), exesome, and cytopharmaceuticals. The company also cooperates with affiliated companies to support the mass production and commercialization of X.MSC-related medical projects.

Website

vitaspring8888.com/

IPO

2019-10-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)